Company CVAbout Strides Pharma Science Ltd 
Strides Pharma Science Ltd
Mid Cap
Pharmaceuticals & Drugs
Strides Pharma Science Limited was originally incorporated under the name 'Strides Arcolab Limited ' on June 28, 1990. In FY 2016, Shasun Pharmaceuticals Limited merged with Strides Arcolab Limited forming a new identity 'Strides Shasun Limited', which became effective from 19 November, 2015 and name of the Company was changed to 'Strides Pharma Science Limited' from 'Strides Shasun Limited' effective on July 18, 2018.
Company Coordinates
Company Details
No 201 Devavrata Sector 17, Vashi Navi Mumbai Maharashtra : 400703
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 91.96 Cr
Number of Shares
9.2 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
29-Jul-2024
9.2
91.96
41500
10
Issued under ESOP Scheme
22-May-2024
9.19
91.92
7000
10
Issued under ESOP Scheme
29-Apr-2024
9.19
91.91
10000
10
Issued under ESOP Scheme
30-Jan-2024
9.19
91.90
14000
10
Issued under ESOP Scheme
30-Oct-2023
9.19
91.89
5350
10
Issued under ESOP Scheme
25-Oct-2023
9.19
91.88
1197510
10
Conversion of Warrants
20-Oct-2023
9.07
90.68
350000
10
Conversion of Warrants
07-Jul-2023
9.03
90.33
30150
10
Issued under ESOP Scheme
14-Nov-2022
9.03
90.30
12500
0
Issued under ESOP Scheme
14-Nov-2022
9.03
90.30
12500
10
Issued under ESOP Scheme
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
FIIs
Pledged Promoter Holdings
54.2473
Mutual Funds
Held by 12 Schemes (10.86%)
FIIs
Held by 236 FIIs (28.48%)
Promoter with highest holding
Pronomz Ventures Llp (18.22%)
Highest Public shareholder
Quant Mutual Fund - Quant Business Cycle Fund (5.4%)
Individual Investors Holdings
20.86%
Board of Directors
Management
Designation
Remuneration
Arun Kumar
Chairperson & M D
6.0 cr
S Sridhar
Non-Exec. & Independent Dir.
22.0 lacs
Bharat D Shah
Non-Exec. & Independent Dir.
22.0 lacs
Manjula Ramamurthy
Company Sec. & Compli. Officer
0
Homi Rustam Khusrokhan
Non-Exec. & Independent Dir.
22.0 lacs
Badree Komandur
Executive Director (Finance)
4.4 cr
Kausalya Santhanam
Non-Exec. & Independent Dir.
22.0 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Finished Goods Purchased
51.832
0%
Finished Goods Purchased
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Goods
1,356.43
88.23%
Other Operating Revenue - Sale of Intellectual Property Rights
81.94
5.33%
Other Operating Revenue - Export Incentives
30.40
1.98%
Pharmaceutical Goods
Pharmaceutical Goods
Other Operating Revenue - Sale of Intellectual Property Rights
Other Operating Revenue - Sale of Intellectual Property Rights
Other Operating Revenue - Export Incentives
Other Operating Revenue - Export Incentives
Stock DNARevenue and Profits:
Net Sales:
1,154 Cr
(Quarterly Results - Dec 2024)
Net Profit:
88 Cr
Pharmaceuticals & Drugs
INR 5,598 Cr (Mid Cap)
21.00
33
0.43%
0.91
7.40%
2.36
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
